Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin.

Original publication

DOI

10.1126/scitranslmed.abf4530

Type

Journal article

Journal

Science Translational Medicine

Publisher

American Association for the Advancement of Science (AAAS)

Publication Date

12/2021

Volume

13